SWM
NBIX icon

Sendero Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History

Sendero Wealth Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-20,944
Closed -$2.86M – 190
2024
Q4 		$2.86M Buy
20,944
+672
+3% +$83.1K 0.43% 50
2024
Q3 		$2.34M Buy
20,272
+537
+3% +$73.6K 0.37% 49
2024
Q2 		$2.72M Buy
19,735
+172
+0.9% +$23.6K 0.46% 45
2024
Q1 		$2.7M Sell
19,563
-254
-1% -$34.7K 0.46% 46
2023
Q4 		$2.61M Buy
19,817
+271
+1% +$31.2K 0.49% 44
2023
Q3 		$2.2M Buy
19,546
+4,899
+33% +$516K 0.47% 45
2023
Q2 		$1.38M Sell
14,647
-1,527
-9% -$149K 0.3% 65
2023
Q1 		$1.64M Buy
16,174
+1,308
+9% +$136K 0.5% 47
2022
Q4 		$1.78M Buy
14,866
+1,257
+9% +$147K 0.63% 28
2022
Q3 		$1.45M Buy
13,609
+755
+6% +$76.6K 0.6% 23
2022
Q2 		$1.25M Buy
12,854
+1,756
+16% +$162K 1.2% 23
2022
Q1 		$1.04M Sell
11,098
-151
-1% -$12.8K 0.48% 28
2021
Q4 		$958K Buy
+11,249
New +$1.03M 0.43% 37

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sendero Wealth Management's NBIX Position: Q1 2025 in Review

Sendero Wealth Management sold out of Neurocrine Biosciences (NBIX) in Q1 2025, closing a stake of 20,944 shares — an estimated $2.86M sold.

Sendero Wealth Management first reported a position in NBIX in Q4 2021 and held it in 13 quarters. The position peaked at $2.86M in Q4 2024. 586 funds tracked by Wall St. Rank hold NBIX as of Q1 2025.

  • Sendero Wealth Management reported no remaining Neurocrine Biosciences position as of Q1 2025 after selling out during the quarter.
  • Sendero Wealth Management sold 20,944 Neurocrine Biosciences shares in Q1 2025, an estimated $2.86M.
  • Sendero Wealth Management first reported a position in Neurocrine Biosciences in Q4 2021 and held it in 13 quarters.
  • Sendero Wealth Management's Neurocrine Biosciences position peaked at $2.86M in Q4 2024.
  • 586 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2025.

Based on Sendero Wealth Management's 13F filing for Q1 2025, filed 10 Apr 2025.